Data on obese and overweight patients with or without diabetes showed those who took the weight-loss drug Qsymia shed more pounds at 56 weeks on either low or high doses of the drug compared with a placebo group. Diabetes patients who took the drug attained a mean HbA1C decline of 1.6%, compared with only 1.2% in the placebo arm, researchers reported at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

Related Summaries